Insight

Aditya Juloori: Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer

Photo taken from Aditya Juloori/X

Aug 14, 2024, 13:00

Aditya Juloori: Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer

Aditya Juloori, Radiation Oncologist at The University of Chicago Medical Center, shared on X:

“Check out our multi-center phase 2 IIT currently accruing for upfront SBRT added to Durvalumab-based chemoimmunotherapy for the first line treatment of extensive stage SCLC – the DARES trial.”

DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer

Authors: Christine M. Bestvina, Jared H. L. Hara, Theodore Karrison, Benjamen Bowar, Janet Chin, Marina C. Garassino, Sean P. Pitroda, Rajat Thawani, Everett E. Vokes, Gregory Gan, Jun Zhang, Andrew M. Baschnagel, Toby C. Campbell, Steven Chmura and Aditya Juloori.

Source: Aditya Juloori/X

Aditya Juloori cancer DARES trial Durvalumab Durvalumab-based chemoimmunotherapy multi-center trial OncoDaily Oncology SCLC The University of Chicago Medical Center

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage